Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
2020 · New England Journal of Medicine · 15K citations
https://doi.org/10.1056/nejmoa2034577
P
Philip R. Dormitzer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
151
Papers
37.6K
Citations
61
h-index
101
i10-index
Philip R. Dormitzer is an academic researcher from Pfizer (United States). The author has contributed to research in topics: Viral gastroenteritis research and epidemiology & Respiratory viral infections research & SARS-CoV-2 and COVID-19 Research. The author has an h-index of 61, co-authored 129 publications.
ORCID: 0000-0003-0671-6360Papers by this author
worksPhase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
2020 · Nature · 1,577 citations
https://doi.org/10.1038/s41586-020-2639-4
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
2021 · New England Journal of Medicine · 913 citations
https://doi.org/10.1056/nejmoa2107456
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
2021 · Nature · 725 citations
https://doi.org/10.1038/s41586-021-03275-y
SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes Cathepsin L to Infect ACE2-expressing Cells
2005 · Journal of Biological Chemistry · 386 citations
https://doi.org/10.1074/jbc.m508381200
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody
2012 · Proceedings of the National Academy of Sciences · 267 citations
https://doi.org/10.1073/pnas.1218256109
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat